Popular on Amzeal
- MC-IF Announces 2025-26 Board of Directors to Advance Next-Generation Media Technologies - 166
- AirGyde Appoints SpaceX Principal Engineer Sanjeev Sharma as Technical Board Advisor - 166
- Post-Oscar Iftar Night Celebrates Academy Award-Winning Documentary No Other Land with a Packed House - 138
- The ADHD Epidemic: How Profit, Not Science, Drives the Surge in Diagnoses
- For Saving Home Services Inc. Helps GTA Homeowners Save with Heat Pump Rebates
- REVOBOTS Unveils TASKBOT at Mobile World Congress 2025
- The NRECC Brings Safety, Efficiency and Same-Day Liquidity to U.S. Real Estate
- Countertop Pro GTA Launches Full-Service Kitchen Remodeling in Greater Toronto
- Have a Special Japanese Honeymoon Experience in Nikko, Japan, With Photoshoot
- Wealthy Americans Look to Change Citizenship to Reduce Tax
Similar on Amzeal
- Choosing the Right Commercial Space for Your Business
- Etan Polinger Officially Recognized As New Mexico's First Certified Ai Consultant
- America Is Being Ripped Off: It's Time To Take Action Against Fraud & Foreign Exploitation
- Independence Title Honored for Excellence in Fraud Prevention by Stewart Title
- Pan-Armenian Digital Trade Center Launched on Fastexverse
- Stern Recruiting Launches with a Mission to Revolutionize Talent Acquisition
- Webinar Announcement: Collaborating for Digital Transformation: Innovation, Governance, and the Future of Financial Operations
- Multi-Million Dollar Contracts and Key Partnerships for Cybersecurity Solutions in the Rapidly Growing Market Nearing $200 Billion Annually $CYCU
- Unveil Hydrogen-Powered Maritime Innovation at H2Hub Summit
- Major Defense Contractor, Satellite and Multiple Deployable Tech Companies Partnering with Ascent Solar Technologies, Inc: Stock Symbol: ASTI
Micron Biomedical Expands World-Renowned Advisory Team with Appointment of Medtech Innovation Leader, Sandeep Patel, PhD Ahead of Commercial Manufacturing of Its Needle-Free Technology
Amzeal News/10574825
Immediate past Director of BARDA's Division of Research, Innovation and Ventures (DRIVe) and health innovation entrepreneur accepts first Board position with a stated mission to make vaccines and treatments more accessible
ATLANTA, Sept. 5, 2024 /PRNewswire/ -- Micron Biomedical, a life science company developing the world's first dissolvable, needle-free microarray-based products that could replace injectable pharmaceuticals and vaccines, today announced the appointment of former BARDA DRIVe Director, Dr. Sandeep Patel, to its Board of Advisors. In this capacity, Dr. Patel will bring his expertise in public health innovation to advance the commercialization of Micron Biomedical's unique technology. Recently, the company announced a grant to fund mass manufacturing of the technology following positive phase 1/2 data.
"Dr. Patel is well-known globally both for championing efficient, impactful and disruptive innovations that transform lives and for his creative, energetic and smart approach to advancing technologies he believes can make a significant and positive impact," said Steven Damon, CEO of Micron Biomedical. "We're thrilled he has decided to join Micron Biomedical as an advisor. As we demonstrate the ability to deliver medications and vaccines in a significantly more convenient, affordable and accessible way, our focus is on continued growth of our product portfolio and Dr. Patel's expertise is critical to our approach to getting needle-free technology into the hands of more people."
More on Amzeal News
Dr. Sandeep Patel was the first Director of BARDA's DRIVe, where he oversaw a diverse portfolio of high-risk, high-reward R&D programs to address existing and emerging health security threats. He also oversaw the development of the US government's first public-private venture capital partnership. Previously, Dr. Patel served in the Secretary's Office of the US Department of Health and Human Services (HHS) where he led multiple initiatives to advance innovative policies and funding solutions to complex, long-standing health problems.
"Globally, we must prioritize the development and commercialization of technologies and business models that can reduce barriers and improve access to vaccines and therapies," said Dr. Sandeep Patel. "There are a few players emerging but I believe Micron Biomedical can be a game-changer in bringing vaccines and therapies to more people around the world."
Dr. Patel joins a Board of Advisors that includes global health pioneer, Dr. Seth Berkley, who was announced as Scientific Advisor to the CEO earlier this year.
About Dr. Sandeep Patel
In addition to his leadership role at BARDA, Dr. Patel co-founded and led a public-private partnership, KidneyX, that catalyzed the development of breakthrough therapies for kidney disease, including renal replacement technologies. He spearheaded the Advancing American Kidney Health Initiative, aimed at reforming the nation's organ transplant system, getting more patients off dialysis, and increasing focus to prevent kidney failure. He led HHS' program to use novel methods, including incentive prizes and crowdsourcing, to solve complex health problems across the family of HHS agencies. He is the recipient of the American Society of Nephrology's President's Medal, and a Secretary's Distinguished Service award. Prior to that he was a Mirzayan Science and Technology Policy Fellow at the National Academy of Sciences.
More on Amzeal News
Dr. Patel holds a PhD in physical chemistry from the Georgia Institute of Technology and a BA in chemistry from Washington University in St. Louis.
About Micron Biomedical
Micron Biomedical is the leader in dissolvable microarray-based, drug and vaccine administration technology. Micron Biomedical is a clinical-stage life science company on a rapid path to commercializing its proprietary dissolvable, microarray technology. Micron's technology is designed to improve access and achieve better health outcomes globally through injection-free, painless, and simple and/or self-administration of drugs and vaccines, and by eliminating or reducing the need for cold chain transport and storage, enhancing safety and efficacy, and improving patient compliance. Micron partners with and/or receives funding from private and public pharmaceutical and biotech companies, the Bill & Melinda Gates Foundation, the Centers for Disease Control and Prevention (CDC), PATH and the Georgia Research Alliance. For more information visit www.micronbiomedical.com
Media Inquiries:
Chrystal Loyer
Cuttlefish Communications
+1 917 280 2498
[email protected]
SOURCE Micron Biomedical, Inc.
ATLANTA, Sept. 5, 2024 /PRNewswire/ -- Micron Biomedical, a life science company developing the world's first dissolvable, needle-free microarray-based products that could replace injectable pharmaceuticals and vaccines, today announced the appointment of former BARDA DRIVe Director, Dr. Sandeep Patel, to its Board of Advisors. In this capacity, Dr. Patel will bring his expertise in public health innovation to advance the commercialization of Micron Biomedical's unique technology. Recently, the company announced a grant to fund mass manufacturing of the technology following positive phase 1/2 data.
"Dr. Patel is well-known globally both for championing efficient, impactful and disruptive innovations that transform lives and for his creative, energetic and smart approach to advancing technologies he believes can make a significant and positive impact," said Steven Damon, CEO of Micron Biomedical. "We're thrilled he has decided to join Micron Biomedical as an advisor. As we demonstrate the ability to deliver medications and vaccines in a significantly more convenient, affordable and accessible way, our focus is on continued growth of our product portfolio and Dr. Patel's expertise is critical to our approach to getting needle-free technology into the hands of more people."
More on Amzeal News
- Announcing The Must-Read Crypto Playbook Of 2025!
- Revolutionizing Motor Copper Plate Brazing with FOCO INDUCTION's Portable Induction Heating Machine
- Etan Polinger Officially Recognized As New Mexico's First Certified Ai Consultant
- Expert Law Attorneys Nominates 2025 Personal Injury Firms
- The Ripple Effect Arts Leverages Social Media to Showcase the Benefits of Magic Magnesium Spray, Driving 200% Audience Growth
Dr. Sandeep Patel was the first Director of BARDA's DRIVe, where he oversaw a diverse portfolio of high-risk, high-reward R&D programs to address existing and emerging health security threats. He also oversaw the development of the US government's first public-private venture capital partnership. Previously, Dr. Patel served in the Secretary's Office of the US Department of Health and Human Services (HHS) where he led multiple initiatives to advance innovative policies and funding solutions to complex, long-standing health problems.
"Globally, we must prioritize the development and commercialization of technologies and business models that can reduce barriers and improve access to vaccines and therapies," said Dr. Sandeep Patel. "There are a few players emerging but I believe Micron Biomedical can be a game-changer in bringing vaccines and therapies to more people around the world."
Dr. Patel joins a Board of Advisors that includes global health pioneer, Dr. Seth Berkley, who was announced as Scientific Advisor to the CEO earlier this year.
About Dr. Sandeep Patel
In addition to his leadership role at BARDA, Dr. Patel co-founded and led a public-private partnership, KidneyX, that catalyzed the development of breakthrough therapies for kidney disease, including renal replacement technologies. He spearheaded the Advancing American Kidney Health Initiative, aimed at reforming the nation's organ transplant system, getting more patients off dialysis, and increasing focus to prevent kidney failure. He led HHS' program to use novel methods, including incentive prizes and crowdsourcing, to solve complex health problems across the family of HHS agencies. He is the recipient of the American Society of Nephrology's President's Medal, and a Secretary's Distinguished Service award. Prior to that he was a Mirzayan Science and Technology Policy Fellow at the National Academy of Sciences.
More on Amzeal News
- America Is Being Ripped Off: It's Time To Take Action Against Fraud & Foreign Exploitation
- Independence Title Honored for Excellence in Fraud Prevention by Stewart Title
- Dentaluxe's New Website Launch!
- PawTides.com Partners with Rescue 22 Foundation to Support Veterans and Rescue Dogs
- Pan-Armenian Digital Trade Center Launched on Fastexverse
Dr. Patel holds a PhD in physical chemistry from the Georgia Institute of Technology and a BA in chemistry from Washington University in St. Louis.
About Micron Biomedical
Micron Biomedical is the leader in dissolvable microarray-based, drug and vaccine administration technology. Micron Biomedical is a clinical-stage life science company on a rapid path to commercializing its proprietary dissolvable, microarray technology. Micron's technology is designed to improve access and achieve better health outcomes globally through injection-free, painless, and simple and/or self-administration of drugs and vaccines, and by eliminating or reducing the need for cold chain transport and storage, enhancing safety and efficacy, and improving patient compliance. Micron partners with and/or receives funding from private and public pharmaceutical and biotech companies, the Bill & Melinda Gates Foundation, the Centers for Disease Control and Prevention (CDC), PATH and the Georgia Research Alliance. For more information visit www.micronbiomedical.com
Media Inquiries:
Chrystal Loyer
Cuttlefish Communications
+1 917 280 2498
[email protected]
SOURCE Micron Biomedical, Inc.
Filed Under: Business
0 Comments
Latest on Amzeal News
- Multi-Million Dollar Contracts and Key Partnerships for Cybersecurity Solutions in the Rapidly Growing Market Nearing $200 Billion Annually $CYCU
- Unveil Hydrogen-Powered Maritime Innovation at H2Hub Summit
- Brookline Family Dentistry Updates Website URL for a Stronger Brand Identity
- Consensus Emerges on Urgent Need for Advanced Video Compression in Mobile Networks -- The Case for VVC
- Major Defense Contractor, Satellite and Multiple Deployable Tech Companies Partnering with Ascent Solar Technologies, Inc: Stock Symbol: ASTI
- Rosann Santos Ofrece el Programa Repensando el Síndrome del Impostor™
- Criptlán Partners with Top Capital and Technology Teams to Drive the Future of the Digital Economy
- From Sea to the Site: The Evolution of the Shipping Container From the Water to the Worksite
- Montel Williams Joins Citizen Green TV to Champion Veteran Wellness and Advocacy
- Inbound Lead Generation for Security Companies in 2025: The Key to Sustainable Growth
- Cytec launches new software solution to enable more effective corporate governance
- BroadSource Appoints Bill Placke as President, Americas
- Frame Up Now Leverages Cyntexa and Salesforce to Fuel Their Operations & Power Up Lead Conversion
- M Film Lab Launches Spring 2025 Screenwriting Lab: Tales of Identity & Imagination
- TFL Tech Inc. Launches New & Improved Website
- The Right Reverend Mariann Edgar Budde, Bishop of the Episcopal Diocese of Washington, Joins Seabury Resources for Aging® Board of Governors
- Aries Industries Celebrates 40 Years of Innovation, Growth and Service
- Electro Standards Laboratories to Attend APEC for IEEE Paper on Dynamic EV Wireless Charging
- Smarter Maintenance Starts Here: iMarq Unveils Enhancements to AI-driven Insights, Inventory Management, and Communication
- Royalty Settlement in Patent Infringement Suit with New Strategic Partnership for AI Marketing Tech Company: Alpha Modus Corp. (Stock Symbol:: AMOD)